THE ADVERSE EFFECT OF TREATMENT PROLONGATION IN CERVICAL-CARCINOMA

被引:234
作者
PETEREIT, DG
SARKARIA, JN
CHAPPELL, R
FOWLER, JF
HARTMANN, TJ
KINSELLA, TJ
STITT, JA
THOMADSEN, BR
BUCHLER, DA
机构
[1] UNIV WISCONSIN,SCH MED,DEPT OBSTET & GYNECOL,MADISON,WI 53706
[2] UNIV WISCONSIN,SCH MED,DEPT BIOSTAT,MADISON,WI 53706
[3] UNIV WISCONSIN,SCH MED,DEPT MED PHYS,MADISON,WI 53706
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 1995年 / 32卷 / 05期
关键词
CERVICAL CANCER; RADIATION; PREDICTORS OF RECURRENCE; PROLIFERATION; COMPLICATIONS; OVERALL TIME;
D O I
10.1016/0360-3016(94)00635-X
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Proliferation of surviving tumor clonogens during a course of protracted radiation therapy may be a cause of local failure in cervical carcinoma. The affect of total treatment time was analyzed retrospectively in relation to pelvic control and overall survival for squamous cell carcinomas of the uterine cervix. Methods and Materials: Two hundred and nine patients (Stage IB-IIIB) treated with a combination of external beam and low dose rate intracavitary irradiation were evaluable for study. Multivariate analysis and Kaplan-Meier statistical methods were used to del:ermine the effect of treatment time on pelvic control and survival at 5 years. Results: The median treatment duration was 55 days. For all stages combined, the 5-year survival and pelvic control rates were significantly different with treatment times < 55 days vs. greater than or equal to 55 days: 65 and 54% (p = 0.03), 87 and 72% (p = 0.006), respectively. By stage, a shorter treatment duration (i.e., < 55 days vs. greater than or equal to 55 days) was significant for 5-year overall survival and pelvic control for Stages IB/IIA and III, but not for Stage IIIB: Stage IB/IIA (81 and 67%, 96 and 84%), Stage III disease (52 and 42%, 76 and 55%) and Stage IIB (43 and 50%, 74 and 80%, respectively). Survival decreased 0.6%/day and pelvic control decreased 0.7%/day for each additional day of treatment beyond 55 days for all stages of disease. Additionally, significant late complications were not influeuced by treatment time. Conclusion: These results suggest-that prolongation of treatment time is associated with decreased local control and survival in patients with cervical carcinoma. This is consistent with emerging data from other institutions. Therapeutic implications include avoidance of unnecessary treatment breaks, the design of fractionation schemes that decrease treatment duration, and possibly the use of tumor cytostatic drugs during conventional radiation.
引用
收藏
页码:1301 / 1307
页数:7
相关论文
共 28 条
[11]   AN ANALYSIS OF THE EFFICACY AND SAFETY OF HIGH-DOSE-RATE AS COMPARED TO LOW-DOSE RATE BRACHYTHERAPY IN THE TREATMENT OF UTERINE CERVICAL-CARCINOMA [J].
HARTMANN, TJ ;
SARKARIA, JN ;
PETEREIT, DG ;
STITT, JA ;
BUCHLER, DA ;
CHAPPELL, R ;
FOWLER, JF ;
KINSELLA, TJ .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1993, 27 :130-130
[12]   SQUAMOUS-CELL CARCINOMA OF THE SUPRAGLOTTIC LARYNX WITHOUT CLINICALLY DETECTABLE LYMPH-NODE METASTASES - PROBLEM OF LOCAL RELAPSE AND INFLUENCE OF OVERALL TREATMENT TIME [J].
HOEKSTRA, CJM ;
LEVENDAG, PC ;
VANPUTTEN, WLJ .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1990, 18 (01) :13-21
[13]   NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481
[14]  
Keane TJ, 1992, SEMIN RADIAT ONCOL, V2, P26
[15]  
LAING JHE, 1992, BR J RADIOL S, V24, P163
[16]   PRETREATMENT AND TREATMENT FACTORS ASSOCIATED WITH IMPROVED OUTCOME IN SQUAMOUS-CELL CARCINOMA OF THE UTERINE CERVIX - A FINAL REPORT OF THE 1973 AND 1978 PATTERNS OF CARE STUDIES [J].
LANCIANO, RM ;
WON, M ;
COIA, LR ;
HANKS, GE .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1991, 20 (04) :667-676
[17]   THE INFLUENCE OF TREATMENT TIME ON OUTCOME FOR SQUAMOUS-CELL CANCER OF THE UTERINE CERVIX TREATED WITH RADIATION - A PATTERNS-OF-CARE STUDY [J].
LANCIANO, RM ;
PAJAK, TF ;
MARTZ, K ;
HANKS, GE .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1993, 25 (03) :391-397
[18]  
MONTANA GS, 1986, CANCER, V57, P148, DOI 10.1002/1097-0142(19860101)57:1<148::AID-CNCR2820570130>3.0.CO
[19]  
2-7
[20]  
PATERSON R, 1963, TREATMENT MALIGNANT, P331